STATEMENT OF NEED
Of the estimated 74,200 new cases of non-Hodgkin lymphoma each year in the United States, approximately 22% are follicular lymphoma (FL), an indolent, difficult-to-treat B-cell malignancy. Most patients are diagnosed at an average age of 63 years. Despite the introduction of novel therapies during the past decade, complications such as delayed presentation and treatment and evolving disease subtypes continue to hamper patient outcomes, and multiple recurrences with available therapies are common. Currently, allogeneic hematopoietic stem cell transplant is the only curative therapeutic modality for relapsed/refractory disease. However, the risk for comorbidities and secondary cancers limits the utility of this treatment upfront. Further research is required to determine the optimal timing and role of transplant and novel therapies to keep the remission rate among FL patients high and durable.
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with FL.
Upon completion of this activity, participants should be able to:
Anas Younes, MD (Chairperson)
Professor of Medicine
Memorial Sloan Kettering Cancer Center
Loretta J. Nastoupil, MD
Assistant Professor of Medicine
MD Anderson Cancer Center
Reem Karmali, MD, MS
Assistant Professor of Medicine
Northwestern Memorial Hospital
There is no fee to participate in or claim CME credit for this activity.
Please note that the University of Cincinnati and i3 Health do not accept responsibility for travel, accommodation, or any other costs incurred by registrants in the rare event that this activity should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Cincinnati and i3 Health. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
The University of Cincinnati designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program.
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS
A conflict of interest is created when individuals in a position to control the content of CE have a relevant financial relationship with a commercial interest which, therefore, may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits. The University of Cincinnati will identify, review and resolve all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. The University of Cincinnati does not endorse any products or services.
Relevant financial relationships exist between the following individuals and commercial interests:
Anas Younes, MD, discloses that he has served as a consultant for Biopath, Celgene, Epizyme, HCM, Roche, and Xynomics. He has also received honoraria from AbbVie, Curis, Epizyme, Janssen, Merck, Roche, and Takeda. Dr. Younes has received research support from Bristol-Myers Squibb, Curis, Janssen, Merck, Roche, and Syndax.
Loretta J. Nastoupil, MD, discloses that she has received honoraria from Bayer, Celgene, Gilead, and Novartis. She has also received research support from Celgene and Genentech.
Reem Karmali, MD, MS, discloses that she has served on the speakers' bureau for AstraZeneca, Celgene/Juno, and Gilead/Kite. She has also served on the advisory board for Celgene/Juno and Gilead/Kite. Dr. Karmali has also received research support from Bristol-Myers Squibb, Celgene/Juno, Gilead/Kite, and Takeda.
University of Cincinnati staff members, i3 Health staff members, and the peer/content reviewers for this activity have no relevant financial relationships to disclose.
Disclosures are on file at the University of Cincinnati, Office of Continuing Medical Education.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.
UNAPPROVED USE DISCLOSURE
The University of Cincinnati and i3 Health require CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
This activity is supported by independent educational grants from Bayer Healthcare Pharmaceuticals and Celgene.
Aggregate participant data will be shared with commercial supporters of this activity.
AMERICANS WITH DISABILITIES ACT